Phentolamine - Repros Therapeutics

Drug Profile

Phentolamine - Repros Therapeutics

Alternative Names: Vasofem; Vasomax; Z-MAX

Latest Information Update: 19 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Repros Therapeutics
  • Developer Industria Quimica e Farmaceutica Schering-Plough; Repros Therapeutics
  • Class Erectile dysfunction therapies; Imidazoles; Peripheral vasodilators; Small molecules
  • Mechanism of Action Alpha adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Erectile dysfunction
  • Discontinued Female sexual dysfunction

Most Recent Events

  • 03 Nov 2003 Discontinued - Phase-I for Female sexual dysfunction in USA (PO)
  • 03 Nov 2003 Discontinued - Phase-I for Female sexual dysfunction in USA (Vaginal)
  • 03 Nov 2003 Discontinued - Preregistration for Erectile dysfunction in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top